Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine-amiodarone interaction

K K Chitwood1, A J Abdul-Haqq, K L Heim-Duthoy

  • 1Drug Evaluation Unit, Hennepin County Medical Center, Minneapolis.

The Annals of Pharmacotherapy
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of lipid-lowering agents on acute renal allograft rejection.

Transplantation·2001
Same author

Variability of Sandimmune pharmacokinetics in renal transplant patients.

Transplantation proceedings·1998
Same author

The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function.

Clinical pharmacology and therapeutics·1998
Same author

A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients.

American journal of kidney diseases : the official journal of the National Kidney Foundation·1997
Same author

Predictive performance of renal function estimate equations in renal allografts.

British journal of clinical pharmacology·1997
Same author

Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.

Transplantation·1995
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
See all related articles

A potential drug interaction between cyclosporine (CsA) and amiodarone was observed in a kidney transplant patient. Close monitoring of CsA levels and dose adjustments are recommended when these medications are used together.

Area of Science:

  • Pharmacology
  • Nephrology
  • Cardiology

Background:

  • Kidney transplant recipients often require immunosuppression with cyclosporine (CsA).
  • Ventricular tachycardia is a serious post-transplant complication requiring treatment.
  • Amiodarone is an antiarrhythmic medication used to treat ventricular tachycardia.

Observation:

  • A kidney transplant recipient on CsA developed ventricular tachycardia and was treated with amiodarone.
  • CsA levels more than doubled after amiodarone initiation.
  • CsA dosage reduction normalized CsA concentrations without toxicity.

Findings:

  • A significant drug interaction between CsA and amiodarone is likely.
  • Potential mechanisms include altered protein binding or cytochrome P-450 metabolism.

Related Experiment Videos

  • This interaction has also been reported in heart transplant recipients.

    • Implications:

    • Concurrent use of CsA and amiodarone necessitates close therapeutic drug monitoring of CsA.
    • Dosage adjustments of CsA may be required to maintain target levels and avoid toxicity.
    • Understanding this interaction is crucial for managing transplant patients on both medications.